Agile Therapeutics - AGRX Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGRX shares.
View AGRX analyst ratings or view top-rated stocks.

2 analysts have issued 1-year target prices for Agile Therapeutics' shares. Their AGRX share price forecasts range from $100.00 to $160.00. On average, they anticipate the company's share price to reach $130.00 in the next year. This suggests a possible upside of 19,747.3% from the stock's current price.
View analysts price targets for AGRX or view top-rated stocks among Wall Street analysts.

Agile Therapeutics' stock was trading at $19.5240 at the beginning of the year. Since then, AGRX shares have decreased by 96.6% and is now trading at $0.6550.
View the best growth stocks for 2022 here.

Agile Therapeutics saw a decline in short interest in July. As of July 15th, there was short interest totaling 772,200 shares, a decline of 73.7% from the June 30th total of 2,940,000 shares. Based on an average trading volume of 9,490,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 2.0% of the company's shares are sold short.
View Agile Therapeutics' Short Interest.

Agile Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our AGRX earnings forecast.

Agile Therapeutics will be holding an earnings conference call on Thursday, August 11th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Agile Therapeutics, Inc. (NASDAQ:AGRX) announced its quarterly earnings data on Thursday, May, 12th. The specialty pharmaceutical company reported ($3.78) EPS for the quarter. The specialty pharmaceutical company earned $1.76 million during the quarter. Agile Therapeutics had a negative trailing twelve-month return on equity of 599.24% and a negative net margin of 1,209.95%.

Shares of Agile Therapeutics reverse split on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGRX stock can currently be purchased for approximately $0.66.

Agile Therapeutics (NASDAQ:AGRX) has a market capitalization of $2.97 million and generates $4.10 million in revenue each year. The specialty pharmaceutical company earns $-74,890,000.00 in net income (profit) each year or ($26.98) on an earnings per share basis.

Agile Therapeutics employs 28 workers across the globe.

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The official website for the company is www.agiletherapeutics.com. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at info@agiletherapeutics.com.